8-K: BioCryst Reports Strong Q2 2024 Results, Raises Full-Year Revenue Guidance for ORLADEYO

BioCryst Pharmaceuticals announced a 34% year-over-year increase in ORLADEYO net revenue for Q2 2024, leading to an increased full-year revenue guidance and a GAAP operating profit.

Summary

• BioCryst Pharmaceuticals reported its financial results for the second quarter of 2024, showing significant growth in ORLADEYO revenue.
• ORLADEYO net revenue reached $108.3 million, a 34% increase compared to the same quarter last year.
• The company has raised its full-year 2024 ORLADEYO revenue guidance to $420-$435 million, up from the previous $390-$400 million.
• BioCryst achieved a GAAP operating profit of $8.8 million in the second quarter, a significant improvement from a $20.7 million loss in the same period last year.
• Non-GAAP operating profit was $21.9 million for the quarter, compared to a non-GAAP operating loss of $7.9 million in the second quarter of 2023.
• Total revenue for the quarter was $109.3 million, a 32.5% increase year-over-year.
• Research and development expenses decreased by 26.6% year-over-year to $37.6 million, primarily due to the discontinuation of the BCX10013 and BCX9930 programs.
• Selling, general, and administrative expenses increased by 20% year-over-year to $61.2 million, driven by commercial expansion.
• The company's net loss for the quarter was $12.7 million, or $0.06 per share, compared to a net loss of $75.3 million, or $0.40 per share, in the second quarter of 2023.
• Cash, cash equivalents, restricted cash, and investments totaled $338.1 million at the end of June 2024.
• The company expects to achieve a full-year operating profit in 2024, be approaching quarterly positive earnings per share and positive cash flow in the second half of 2025, and be profitable on an EPS basis with positive cash flow for the full year 2026.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased guidance, and a move towards profitability. The discontinuation of one program is a minor setback, but the overall tone is optimistic.

Positives

• ORLADEYO sales are growing strongly, with a 34% year-over-year increase in Q2 2024.
• The company has increased its full-year revenue guidance for ORLADEYO, indicating strong market confidence.
• BioCryst achieved a GAAP operating profit in Q2 2024, a significant turnaround from the previous year's loss.
• The company is making progress on its pipeline, with plans to advance multiple programs into clinical trials.
• The company is seeing strong patient retention with more than 60% of patients on paid therapy staying on for at least a year.
• A market research study showed that 52% of allergist/immunologists are extremely likely to prescribe ORLADEYO to more patients, up from 29% in early 2023.
• The company expects to achieve full-year operating profit in 2024 and be profitable on an EPS basis with positive cash flow for the full year 2026.

Negatives

• The company is discontinuing development of BCX10013 due to insufficient clinical activity.
• The company reported a net loss of $12.7 million for the quarter, although this is a significant improvement from the previous year.
• Cash reserves have decreased from $415.7 million in June 2023 to $338.1 million in June 2024.
• Selling, general, and administrative expenses increased by 20% year-over-year.

Risks

• The company's ability to successfully commercialize ORLADEYO is crucial for future growth.
• The discontinuation of BCX10013 development may impact the company's pipeline.
• The company's pipeline development plans may face delays or setbacks.
• The company's financial projections may not be met due to market factors or operational challenges.
• The company's ability to achieve profitability and positive cash flow may be delayed.

Future Outlook

BioCryst expects to achieve a full-year operating profit in 2024, be approaching quarterly positive earnings per share and positive cash flow in the second half of 2025, and be profitable on an EPS basis with positive cash flow for the full year 2026. The company believes it can achieve these milestones without raising additional funds.

Management Comments

• The first half of 2024 has been outstanding for BioCryst due to the success we are having in the marketplace with ORLADEYO.
• We are increasing our full year guidance for ORLADEYO, advancing multiple programs toward the clinic in the next 18 months and moving the company closer to profitability.
• Our second quarter revenue growth and increased full year guidance for ORLADEYO reflect strong underlying demand and favorable patient outcomes, combined with our continuing focus on improving patient services and market access operations.
• The potential for patients to have that high level of HAE attack control in a once-daily pill is a major differentiator in the marketplace that makes ORLADEYOs trajectory toward $1 billion in peak sales increasingly clear.

Industry Context

The announcement highlights BioCryst's strong performance in the rare disease market, particularly with ORLADEYO. The company's focus on oral small-molecule therapeutics aligns with a growing trend in the pharmaceutical industry towards more convenient and patient-friendly treatments. The discontinuation of BCX10013 development reflects the challenges in drug development and the need for companies to prioritize promising candidates.

Comparison to Industry Standards

• BioCryst's 34% year-over-year growth in ORLADEYO revenue is strong compared to other companies in the rare disease space, such as Alexion Pharmaceuticals (now part of AstraZeneca) which has seen more modest growth in their rare disease portfolio.
• The company's move towards profitability is a positive sign, as many biotech companies struggle to achieve profitability in the early stages of commercialization. Companies like Vertex Pharmaceuticals, which has a successful cystic fibrosis franchise, serve as a benchmark for achieving sustained profitability in the rare disease market.
• The discontinuation of BCX10013 is not uncommon in the industry, as many drug candidates fail to meet clinical endpoints. Companies like Alnylam Pharmaceuticals have also had to discontinue programs due to lack of efficacy or safety concerns.
• BioCryst's focus on oral therapies is a competitive advantage, as many treatments for rare diseases are administered intravenously or through injections. This is similar to the strategy of companies like Global Blood Therapeutics, which developed an oral therapy for sickle cell disease.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and increased revenue guidance.
• Employees may feel more secure due to the company's improved financial position and future outlook.
• Patients will benefit from the continued availability and potential expansion of ORLADEYO.
• The company's suppliers and creditors may have increased confidence in the company's ability to meet its obligations.

Next Steps

• Submit a regulatory filing in 2025 to expand the ORLADEYO label to include children as young as two years of age.
• Advance BCX17725 into the clinic by the end of 2024.
• Advance avoralstat into a clinical trial for diabetic macular edema in 2025.

Key Dates

Keywords

ORLADEYO, BioCryst, Hereditary Angioedema, HAE, Rare Disease, Financial Results, Revenue, Operating Profit, Pipeline, BCX17725, Avoralstat, Net Loss